Treatment of oesophageal varices;Behandling af esophagusvaricer

Ugeskrift for Laeger

Volumn 163, Issue 11, 2001, Pages 1552-1556

  Bendtsen, Flemming ^a   Becker, Povl Ulrik ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE DINITRATE; SPIRONOLACTONE; TERLIPRESSIN;

BLEEDING; ENDOSCOPY; ESOPHAGUS VARICES; HUMAN; LIGATION; MORTALITY; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SCLEROTHERAPY; TREATMENT PLANNING;

ADRENERGIC BETA-ANTAGONISTS; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGOSCOPY; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIGATION; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, SURGICAL; PRACTICE GUIDELINES; SCLEROSING SOLUTIONS; SCLEROTHERAPY;

EID: 0343774052     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn H, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-24.
2. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800-9.
3. The North Italian Endoscopic Club for The Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988; 319: 983-9.
4. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994; 64: 65-107.
5. Bendtsen F, Henriksen JH, Sørensen TIA. Propranolol and splanchnic haemodynamic response in cirrhosis. J Hepatol 1991; 13: 144-8.
6. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 23: 322-54.
7. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of iso-sorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113:1632-9.
8. Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31: 324-9.
9. Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P et al. Effects of low-sodium diet and spironolacton on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19: 1095-9.
10. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients. Randomized multicenter trial. Hepatology 1991; 14: 1016-24.
11. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopie ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988-93.
12. Hartigan P, Gebhard RL, Gregory PB, for the Veterans Affairs Cooperative Variceal Sclerotherapy Group. Sclerotherapy for actively bleeding oesophageal varices in male alcoholics with cirrhosis. Gastrointest Endosc 1997; 46: 1-7.
13. Groszmann RJ, Bendtsen F, Bosch J, Fleig W, Grace N, Lebrec D et al. Baveno II Consensus Statements: drug therapy for portal hypertension. I: De Franchis R, ed. Portal hypertension II. Proceedings of the Second International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. London: Blackwell Science Ltd, 1996: 98-9.
14. Becker PU, Bendtsen F. Terlipressinacetat. Ugeskr Læger 1997; 159: 5399-402.
15. Soderlund C, Magnusson I, Torngfen S, Lundell L. Terlipressin (triglycyllysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled study. Scand J Gastroenterol 1990; 25: 622-30.
16. Freeman JG, Cobden MD, Record CO. Placebo-controlled trial of Terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989; 11: 58-60.
17. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices. A placebo controlled double-blind study. Hepatology 1986; 6: 112-5.
18. Patch D, Caplin M, Greenslade L, Burroughs A. Randomised double blind controlled trial of 5 day terlipressin vs placebo in acute variceal haemorrhage. J Hepatol 1999; 30 (suppl 1): 55.
19. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8.
20. Gøtzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices (Cochrane Review). I: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
21. Cirera I, Feu F, Luca A, Garcia-Pagan J, Fernandez M, Escorsell A et al. Effects of bolus injections and continuous infusions of Somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995: 22; 106-11.
22. Avgerinos A, Klonis A, Rekoumis G, Gouma P, Papedimitriou N. Controlled trial of somatostatin and balloon tamponade in bleeding oesophageal varices. J Hepatol 1991; 13: 78-83.
23. Sung JJ, Chung SC, Lai CW, Chan FK, Leung JW, Yung MY et al. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet 1993; 342: 637-41.
24. Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT et al. Prospective randomized study of effect of octreotide on rebleeding from oesophageal varices after endoscopie ligation. Lancet 1995; 346: 1666-9.
25. Chojkier M, Conn HO. Esophageal tamponade in the treatment of bleeding varices. A decadel progress report. Dig Dis Sci 1980; 25: 267-72.
26. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1996; 22: 1591-7.
27. Laberge JM, Somberg KA, Lake JR, Gordon RL, Kerlan RK, Ascher NL et al. Two-years outcome following transjugular intra-hepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108: 1143-51.
28. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-7.
29. Lind CD, Malisch TW, Chog WK, Riichards WO, Pinson Cv, Meranze SG et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic shunt placement. Gastroenterology 1994; 106: 1277-83.
30. Patch D, Burroughs AK. »Salvage« TIPS for uncontrolled variceal bleeding. Arroy V, Bosch S, Bruguera M, Rodés J, eds. Therapy in liver diseases. Barcelona: Masson, S.A., 1999: 19-23.
31. The Copenhagen Esophageal Varices Sclerotherapy Project. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter study. N Engl J Med 1984; 311: 1594-600.
32. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997; 26: 312-24.
33. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of oesophageal variceal bleeding. A metaanalysis. Ann Intern Med 1995; 123: 280-5.
34. Bjøro K, Friman S, Høckerstedt K, Kirkegaard P, Keiding S, Schrumpf E et al. Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results. Scand J Gastroenterol 1999; 34: 714-22.
35. Luca A, D'Amico G, La Galla R, Midiri M, Morabito M, Pagliaro L. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in patients with cirrhosis: a meta-analysis of randomized controlled trials. Radiology 1999; 212: 411-21.
36. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology 1999; 29: 344-9.